Hong Kong Stocks Update | JD HEALTH (06618) Surges Over 10% Again, Gaining More Than 20% Post-Earnings as AI and Instant Retail Strategies Continue to Drive Positive Growth

Stock News
08/18

JD HEALTH (06618) surged over 10% again, with cumulative gains exceeding 20% following its earnings announcement. As of press time, the stock rose 9.71% to HK$67.2, with trading volume reaching HK$1.073 billion.

On the news front, JD HEALTH recently released its first-half results. Huatai Securities noted that JD HEALTH achieved total revenue of 35.29 billion yuan in the first half of this year, representing a 24.5% year-on-year increase, which exceeded the market consensus expectation of 20.2% growth. The firm believes JD HEALTH is well-positioned to continue benefiting from the rapid traffic growth of JD's main platform (according to QuestMobile, JD APP's daily active users (DAU) grew 44.8%, 33.4%, and 46.4% year-on-year in May, June, and July 2025 respectively). While benefiting from increased advertising demand from upstream partners, the company is gradually retaining new users through its continuously strengthening omnichannel healthcare service capabilities (B2C+O2O). Additionally, JD HEALTH's active practices in medical AI will serve as an important lever for continuously improving operational efficiency and optimizing user experience.

CICC believes JD HEALTH's 1H25 results exceeded market expectations. By business segment, the company achieved product revenue of 29.33 billion yuan (+22.7% YoY) and service revenue of 5.96 billion yuan (+34.4% YoY), demonstrating strong overall performance. The firm calculated that 2Q25 single-quarter revenue reached 18.65 billion yuan (+23.7% YoY), and estimates that JD Group's instant retail traffic investment activities during 1H may have indirectly brought traffic guidance benefits to JD HEALTH. As of the end of 1H25, the company's last twelve months (LTM) active user count exceeded 200 million, reaching a historical high. Meanwhile, the firm expects the pharmaceutical category may have achieved growth rates higher than overall revenue during 1H, remaining the core driving category. Furthermore, the firm believes that while the company remains committed to its AI and offline retail system business layout, under an anti-involution tone, overall investment may be somewhat controlled, bringing positive contributions to the full-year fundamentals.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10